Literature DB >> 7508873

Vanadate augments insulin-stimulated insulin receptor kinase activity and prolongs insulin action in rat adipocytes. Evidence for transduction of amplitude of signaling into duration of response.

I G Fantus1, F Ahmad, G Deragon.   

Abstract

Vanadate, a protein tyrosine phosphatase inhibitor, preserves insulin-stimulated lipogenesis after removal of insulin. To investigate the mechanism of this action of vanadate, lipogenesis was studied in isolated rat adipocytes exposed to vanadate for 60 min followed by insulin for 15 min at 37 degrees C. Vanadate (10-50 microM) prolonged insulin-stimulated lipogenesis. The half-time (t1/2) of the decay in insulin (0.34 nM)-stimulated lipogenesis after removal of insulin by washing in pH 7.0 followed by pH 7.6 buffer was 21 min in the absence and 59 min in the presence of vanadate. During these conditions, vanadate did not alter insulin binding nor the removal of insulin by the series of washes. In contrast to lipogenesis, the t1/2 of the decay in insulin receptor tyrosine kinase (IRK) activity, assayed with the artificial substrate Poly[Glu:Tyr] (4:1), was not significantly prolonged by vanadate (6 vs. 6.8 min). However, insulin-stimulated IRK activity was markedly augmented by vanadate to 319 +/- 19% of insulin alone, associated with a similar augmentation of phosphotyrosine incorporation into the insulin receptor beta-subunit determined by Western blotting with antiphosphotyrosine antibodies. To determine the relationship between prolongation of lipogenesis and the increase in IRK, adipocytes were exposed to 17.2 nM insulin to activate the IRK to the same extent as insulin (0.34 nM) plus vanadate (maximum activation). During these two conditions, the decay of lipogenesis was similar and after stimulation with 17.2 nM insulin was not prolonged by vanadate. We conclude that vanadate prolongs insulin action at insulin concentrations that do not maximally activate the IRK by augmenting IRK activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508873     DOI: 10.2337/diab.43.3.375

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

Review 1.  Alternative therapies for diabetes and its cardiac complications: role of vanadium.

Authors:  Tod A Clark; Justin F Deniset; Clayton E Heyliger; Grant N Pierce
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

Review 2.  Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling.

Authors:  I G Fantus; G Deragon; R Lai; S Tang
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

Review 3.  Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects.

Authors:  I G Fantus; E Tsiani
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

Review 4.  Unique and selective mitogenic effects of vanadate on SV40-transformed cells.

Authors:  H Wang; R E Scott
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

5.  Decrease in protein tyrosine phosphatase activities in vanadate-treated obese Zucker (fa/fa) rat liver.

Authors:  S Pugazhenthi; F Tanha; B Dahl; R L Khandelwal
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

6.  Vanadium salts stimulate mitogen-activated protein (MAP) kinases and ribosomal S6 kinases.

Authors:  S K Pandey; J L Chiasson; A K Srivastava
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

7.  Inhibition of cyclic AMP dependent protein kinase by vanadyl sulfate.

Authors:  Kioumars A Jelveh; Rachel Zhande; Roger W Brownsey
Journal:  J Biol Inorg Chem       Date:  2006-02-28       Impact factor: 3.358

8.  Trace elements in diabetic cardiomyopathy: An electrophysiological overview.

Authors:  Nihal Ozturk; Yusuf Olgar; Semir Ozdemir
Journal:  World J Diabetes       Date:  2013-08-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.